Deal title |
Principal company |
Partner company |
Total projected at signing (US$M) |
Start date |
March | ||||
3D Signatures and Mdxhealth to evaluate Telo-PC test for prostate cancer using 3DS' Teloview software platform |
3D Signatures Inc. |
Mdxhealth SA |
Payment Unspecified |
3/28/18 |
Celgene to develop Abide's ABX-1772 for epilepsy worldwide |
Abide Therapeutics Inc. |
Celgene Corp. |
Payment Unspecified |
3/28/18 |
Forma to use Arpeggio's technology to explore translational utility of drug candidates |
Arpeggio Biosciences |
Forma Therapeutics Inc. |
Payment Unspecified |
3/26/18 |
Undisclosed Korean specialty pharmaceutical company to commercialize Canchew+ and Medchew in South Korea |
Axim Biotechnologies Inc. |
Undisclosed |
Payment Unspecified |
3/30/18 |
GDCC to develop and commercialize Biscayne's BIS-001ER for epilepsy in China, Taiwan, Hong Kong and Macau |
Biscayne Neurotherapeutics Inc. |
China Global Bio-Pharmaceutical Industry Development (Chengdu) Co. Ltd. |
Payment Unspecified |
3/28/18 |
Indivior to develop and commercialize C4X Discovery's C4-X3256 and other compounds in the same patent family for addiction, worldwide |
C4X Discovery Holdings plc |
Indivior plc |
$294.00 |
3/29/18 |
Carna Biosciences and Sumitomo to discover, develop and commercialize novel kinase inhibitors for psychiatric and neurological disorders worldwide |
Carna Biosciences Inc. |
Sumitomo Dainippon Pharma Co. Ltd. |
$94.60 |
3/27/18 |
Biostem to develop CCM's multiple solid-to-liquid dose drugs against cardiovascular, metabolic and central nervous system diseases |
CCM Pharma Solutions |
Biostem Technologies Inc. |
Payment Unspecified |
3/26/18 |
Acerus Pharmaceuticals to commercialize Metuchen Pharmaceuticals' Stendra for erectile dysfunction in Canada |
Metuchen Pharmaceuticals LLC |
Acerus Pharmaceuticals Corp. |
Payment Unspecified |
3/28/18 |
Sinovant to develop and commercialize Nabriva's lefamulin for community-acquired bacterial pneumonia in China, Hong Kong, Macau and Taiwan |
Nabriva Therapeutics AG |
Sinovant Sciences Ltd. |
$100.50 |
3/26/18 |
Nanomedsyn to evaluate Shire's enzyme replacement therapy for a lysosomal storage disorder using its Amfa technology |
Nanomedsyn |
Shire plc |
Payment Unspecified |
3/26/18 |
Chlitina to develop Pacgen's PAC-113 based skin care products |
Pacgen Life Science Corp. |
Chlitina Holding Ltd. |
Payment Unspecified |
3/28/18 |
Polypeptide to manufacture Scancell's Modi-1-Amplivant conjugate for cancer |
Polypeptide Group |
Scancell Ltd. |
Payment Unspecified |
3/31/18 |
Kyorin to develop and commercialize Sanwa Kagaku's SK-1404 for nocturia in Japan and Asia (Hong Kong, Taiwan and 10 countries of Association of Southeast Asian Nations) |
Sanwa Kagaku Kenkyusho Co. Ltd. |
Kyorin Pharmaceutical Co. Ltd. |
Payment Unspecified |
3/29/18 |
Neopharma to commercialize SBI Pharmaceuticals' 5-ALA, including Alaglio, in the Middle East, North Africa and India |
SBI Pharmaceuticals Co. Ltd. |
Neopharma Japan Co. Ltd. |
Payment Unspecified |
3/30/18 |
Rhythm to develop and commercialize Takeda's T-3525770 for Prader-Willi syndrome worldwide |
Takeda Pharmaceutical Co. Ltd. |
Rhythm Pharmaceuticals Inc. |
$5.00 |
3/30/18 |
Novarock Biotherapeutics to use Trianni's mouse in monoclonal antibody discovery research |
Trianni Inc. |
Novarock Biotherapeutics Ltd. |
Payment Unspecified |
3/28/18 |
Curadim Pharma to develop and commercialize UBE Industries' lysophosphatidic acid 1 receptor antagonist for idiopathic pulmonary fibrosis and non-alcoholic steatohepatitis worldwide |
UBE Industries Ltd. |
Curadim Pharma Co. Ltd. |
Payment Unspecified |
3/27/18 |
Takeda to develop and commercialize Valeant's Ammonul for urea cycle disorder in Japan |
Valeant Pharmaceuticals Ireland Ltd. |
Takeda Pharmaceutical Co. Ltd. |
Payment Unspecified |
3/28/18 |
Venbio Partners to use Ligand Pharmaceuticals' Omniab platform to discover fully human mono- and bispecific antibodies worldwide |
Venbio Partners |
Ligand Pharmaceuticals Inc. |
Payment Unspecified |
3/30/18 |
Zeria Pharmaceutical to develop and commercialize Vifor Pharma's Veltassa for hyperkalemia in Japan |
Vifor Pharma Group |
Zeria Pharmaceutical Co. Ltd. |
Payment Unspecified |
3/27/18 |
April | ||||
Producto Científicos to market Acerus' Natesto for male hypogonadism in 19 Central and Latin American countries |
Acerus Pharmaceuticals Corp. |
Carnot Laboratorios |
Payment Unspecified |
4/13/18 |
Cipher Pharmaceuticals to commercialize Aclaris Therapeutics' A-101 40% for seborrheic keratoses in Canada |
Aclaris Therapeutics Inc. |
Cipher Pharmaceuticals Inc. |
$1 |
4/6/18 |
Tonghua to develop and commercialize Adocia's Biochaperone Combo and Biochaperone Lispro for diabetes in China |
Adocia SAS |
Tonghua Dongbao Pharmaceutical Co. Ltd. |
$135 |
4/26/18 |
Advantagene and BMS to evaluate efficacy of Gene Mediated Cytotoxic Immunotherapy in combination with Opdivo for malignant glioma |
Advantagene Inc. |
Bristol-Myers Squibb Co. |
Payment Unspecified |
4/27/18 |
ANI Pharmaceuticals to acquire five approved generic abbreviated new drug applications (three commercialized), plus Erythromycin immediate-release tablets |
Amneal Pharmaceutical LLC and Impax Laboratories Inc. |
ANI Pharmaceuticals Inc. |
Payment Unspecified |
4/27/18 |
ANI Pharmaceuticals to supply and distribute Amneal's Diclofenac-Misoprostol delayed-release tablets to treat arthritis |
Amneal Pharmaceutical LLC |
ANI Pharmaceuticals Inc. |
Payment Unspecified |
4/27/18 |
Applied Biomath to perform semi-mechanistic pharmacokinetic/pharmacodynamic modeling to analyze Xencor's XmAb-24306 for solid tumors |
Applied Biomath LLC |
Xencor Inc. |
Payment Unspecified |
4/18/18 |
Basilea Pharmaceutica to develop and commercialize Arqule's derazantinib worldwide, excluding China, Hong Kong, Macau and Taiwan |
Arqule Inc. |
Basilea Pharmaceutica International Ltd. |
$336.00 |
4/17/18 |
BB100 to acquire worldwide preclinical development rights for Arsanis ASN-200 program with option for worldwide clinical development and commercial license |
Arsanis Inc. |
BB100 LLC |
Payment Unspecified |
4/4/18 |
Cardurion to research, develop, manufacture and commercialize Astellas' CRD-733 for the diagnosis, prevention and treatment of cardiovascular-related indications worldwide |
Astellas Pharma Inc. |
Cardurion Pharmaceuticals LLC |
Payment Unspecified |
4/16/18 |
Avella to distribute Otsuka America's Jynarque for polycystic kidney disease in the U.S. |
Avella |
Otsuka America Pharmaceutical Inc. |
Payment Unspecified |
4/27/18 |
Janssen to develop and commercialize BMS-986177 for the prevention and treatment of major thrombotic conditions |
Bristol-Myers Squibb Co. |
Janssen Pharmaceuticals Inc. |
Payment Unspecified |
4/16/18 |
BSP to produce Annamycin against acute leukemia for Moleculin in Italy |
BSP Pharmaceuticals SpA |
Moleculin Biotech Inc. |
Payment Unspecified |
4/24/18 |
C4X Discovery Holdings and E-therapeutics to identify novel intervention strategies with the potential to treat Parkinson's disease |
C4X Discovery Holdings plc |
E-therapeutics plc |
Unknown |
5/1/18 |
Undisclosed California-based company to sign letter of intent to develop and market Callitas Health's Cannamint strips for tetrahydrocannabinol and cannabidiol |
Callitas Health Inc. |
Undisclosed |
Payment Unspecified |
4/16/18 |
Crystalgenomics and CBT Pharmaceuticals to jointly develop and commercialize the combination of CBT-501 and CG200745 for a variety of solid tumors worldwide |
CBT Pharmaceuticals Inc. |
Crystalgenomics Inc. |
Payment Unspecified |
4/23/18 |
Allogene to develop and commercialize Cellectis' allogeneic UCAR-T programs for cancer worldwide |
Cellectis SA |
Allogene Therapeutics Inc. |
$2,800 |
4/3/18 |
Chr Hansen to manufacture and supply Prota Therapeutics with a pharmaceutical quality LGG1 probiotic strain, Lactobacillus rhamnosus, against peanut allergy |
Chr Hansen Group |
Prota Therapeutics Pty Ltd. |
Payment Unspecified |
4/18/18 |
Medimmune to develop and commercialize Compugen's bispecific and multi-specific immuno-oncology antibody products |
Compugen Ltd. |
Medimmune LLC |
$210 |
4/2/18 |
CPC Scientific to supply Biosim with cGMP adrenocorticotropic hormone (ACTH) peptide |
CPC Scientific |
Biosim Pharmaceuticals LLC |
Payment Unspecified |
4/24/18 |
Xbiotech to develop and commercialize CT Atlantic's 12D7 for cancer |
CT Atlantic AG |
Xbiotech Inc. |
Payment Unspecified |
4/2/18 |
Daiichi to use Darwinhealth's novel cancer target database and technology to identify new targets for cancer drug development |
Darwinhealth |
Daiichi Sankyo Co Ltd. |
Payment Unspecified |
4/4/18 |
Riemser Pharma to develop and market Eisai's Prialt against non-opioid severe chronic pain in Europe |
Eisai Co. Ltd. |
Riemser Pharma GmbH |
Payment Unspecified |
4/23/18 |
Terns to develop and commercialize Eli Lilly's three nonalcoholic steatohepatitis assets worldwide, including China |
Eli Lilly and Co. |
Terns Pharmaceuticals Inc. |
Payment Unspecified |
4/4/18 |
Eli Lilly and SK Chemical to co-market Forsteo against osteoporosis in South Korea |
Eli Lilly and Co. |
SK Chemicals Co. Ltd. |
Payment Unspecified |
4/19/18 |
Zai Lab to develop and commercialize Entasis Therapeutics' ETX-2514 for Acinetobacter baumannii infections in the Asia-Pacific region, including Japan |
Entasis Therapeutics Inc. |
Zai Lab Ltd. |
$103.60 |
4/25/18 |
Zhejiang Teruisi Biopharmaceutical to develop Epimab's FIT-012/TRS-008 against oncology worldwide, excluding China |
Epimab Biotherapeutics Inc. |
Zhejiang Teruisi Pharmaceutical Inc. |
$21.00 |
4/23/18 |
Evonik to manufacture and supply Innovation Pharmaceuticals' brilacidin for bacterial infection |
Evonik Industries AG |
Innovation Pharmaceuticals Inc. |
Payment Unspecified |
4/23/18 |
Petra Pharma and Evotec to develop Petra-01 for cancer using the Indigo platform |
Evotec AG |
Petra Pharma Corp. |
Payment Unspecified |
4/11/18 |
Mylan to commercialize Fujifilm Kyowa's biosimilar FKB-327 against rheumatoid arthritis in Europe |
Fujifilm Kyowa Kirin Biologics Co. Ltd. |
Mylan Inc. |
Payment Unspecified |
4/11/18 |
Fujirebio and Janssen to develop and commercialize Amyloid beta 42/40 ratio assay for Alzheimer's dementia |
Fujirebio Inc. |
Janssen Pharmaceuticals Inc. |
Payment Unspecified |
4/26/18 |
Axxam to support clinical trials to develop Gensight's GS-030 for sight-threatening ophthalmic diseases, such as retinitis pigmentosa |
Gensight Biologics SA |
Axxam SpA |
Payment Unspecified |
4/24/18 |
Orchard Therapeutics to acquire GSK's portfolio of approved and investigational rare disease gene therapies |
Glaxosmithkline plc |
Orchard Therapeutics Ltd. |
Payment Unspecified |
4/12/18 |
Glenmark Pharmaceuticals to distribute Helsinn's Akynzeo in India and Nepal |
Helsinn Group |
Glenmark Pharmaceuticals Ltd. |
Payment Unspecified |
4/4/18 |
BMS and Illumina to develop and commercialize in vitro diagnostic assays worldwide for oncology immunotherapies |
Illumina Inc. |
Bristol-Myers Squibb Co. |
Payment Unspecified |
4/13/18 |
Biogen and Ionis to develop antisense drug candidates for neurological diseases |
Ionis Pharmaceuticals Inc. |
Biogen Inc. |
$1,270.00 |
4/20/18 |
Iontas and Igem Therapeutics to identify novel immunoglobulin E antibodies for cancer targets |
Iontas Ltd. |
Igem Therapeutics Ltd. |
Payment Unspecified |
4/4/18 |
Fusion Pharmaceuticals to use Isogenica's CIS Display technology to discover, develop and commercialize polypeptide therapeutic products |
Isogenica Ltd. |
Fusion Pharmaceuticals |
Payment Unspecified |
4/18/18 |
Dare Bioscience to develop and commercialize Juniper's intravaginal ring (IVR) technology platform, including three preclinical IVR candidates targeting unmet needs in women's health worldwide |
Juniper Pharmaceuticals Inc. |
Dare Bioscience Inc. |
$131.60 |
4/24/18 |
Constance Therapeutics and Kanabo to cultivate and manufacture medical cannabis |
Kanabo Research Ltd. |
Constance Therapeutics Inc. |
Payment Unspecified |
4/25/18 |
Genentech and Kineta to develop alpha 9/alpha 10 nicotinic acetylcholine receptor antagonists for the treatment of chronic pain |
Kineta Chronic Pain LLC |
Genentech Inc. |
$359.00 |
4/16/18 |
Kymera Therapeutics and GSK to develop E3 ligases targeted protein degradation |
Kymera Therapeutics LLC |
Glaxosmithkline plc |
Payment Unspecified |
4/4/18 |
Leadxpro and Interax to discover and optimize new drug lead molecules targeting G protein-coupled receptor for cancer |
Leadxpro AG |
Interax Biotech AG |
Payment Unspecified |
4/18/18 |
Mylan to develop and commercialize Mapi Pharma's glatiramer acetate for multiple sclerosis worldwide |
Mapi Pharma Ltd. |
Mylan Inc. |
Payment Unspecified |
4/10/18 |
Miltenyi to supply Clinimacs Prodigy instruments, reagents and disposables to manufacture Autolus' programmed T cell therapies against cancer |
Miltenyi Biotec GmbH |
Autolus LLC |
Payment Unspecified |
4/4/18 |
Miodx and Diacarta to develop a diagnostic test for the prediction of patient response to immunotherapy |
Miodx Inc. |
Diacarta LLC |
Payment Unspecified |
4/16/18 |
Searchlight Pharma to commercialize Mithra's Estelle for contraceptive use in Canada |
Mithra Pharmaceuticals SA |
Searchlight Pharma Inc. |
$68.43 |
4/12/18 |
Recordati acquires Mylan's Cystagon for nephropathic cystinosis for certain territories, including Europe |
Mylan Inc. |
Recordati SpA |
Payment Unspecified |
4/9/18 |
Mylan to develop and commercialize Prayog's fast-acting Meloxicam against pain worldwide |
Mylan Inc. |
Prayog Labs LLC |
Payment Unspecified |
4/11/18 |
Mymetics to test virosome-based vaccine against Anergis' Allert for birch allergy worldwide |
Mymetics Corp. |
Anergis SA |
Payment Unspecified |
4/16/18 |
Nobelpharma and LTT Bio-pharma to research and development of drug repositioning, including clinical trials in neurology |
Nobelpharma Co. Ltd. |
LTT Bio-pharma Co. Ltd. |
Unknown |
4/13/18 |
Trigen to distribute Optibiotix's Cholbiome products in Pakistan |
Optibiotix Health plc |
Trigen Pharma International Pvt Ltd. |
Payment Unspecified |
4/18/18 |
Cambridge Commodities to distribute Optibiotix's Slimbiome in the U.K. |
Optibiotix Health plc |
Cambridge Commodities |
Payment Unspecified |
4/24/18 |
OSE Immunotherapeutics and Boehringer to develop and commercialize OSE-172 against advanced solid tumors worldwide |
OSE Immunotherapeutics SA |
Boehringer Ingelheim International GmbH |
$1,388.66 |
4/4/18 |
NT Pharma to develop and commercialize Pfenex's PF-708 for osteoporosis in mainland China, Hong Kong, Singapore, Malaysia and Thailand |
Pfenex Inc. |
NT Pharma (Group) Co. Ltd. |
$25.00 |
4/18/18 |
Allogene to purchase Pfizer's portfolio of assets related to allogeneic CAR T-cell therapy worldwide |
Pfizer Inc. |
Allogene Therapeutics Inc. |
Unknown |
4/3/18 |
Pharmaron to conduct a phase I study of Neurop's NMDA NR2B antagonists for several neurological disorders |
Pharmaron Inc. |
Neurop Inc. |
Payment Unspecified |
4/12/18 |
Plexxikon to identify novel drug targets using Phoremost's Siteseeker technology against cancer |
Phoremost Ltd. |
Plexxikon Inc. |
Payment Unspecified |
4/16/18 |
Proniras to develop Eli Lilly's tezampanel for migraine worldwide |
Proniras Corp. |
Eli Lilly and Co. |
Payment Unspecified |
4/27/18 |
UCB to acquire Proximagen's Midazolam nasal spray for acute repetitive seizures in epilepsy |
Proximagen Group plc |
UCB SA |
$370.00 |
4/20/18 |
Pint Pharma to commercialize Puma Biotechnology's Nerlynx in Latin America |
Puma Biotechnology Inc. |
Pint Pharma GmbH |
$34.50 |
4/3/18 |
Q Therapeutics and Reprocell to form JV Magiq Therapeutics to develop demyelinating and degenerative diseases of the central nervous system |
Q Therapeutics Inc. |
Reprocell Inc. |
Unknown |
4/23/18 |
Vertex to use Q-State's novel Optopatch drug discovery platform to discover drugs for neurological disease |
Q-State Biosciences Inc. |
Vertex Pharmaceuticals Inc. |
Payment Unspecified |
4/4/18 |
Durbin to distribute Race Oncology's Bisantrene for acute myelogenous leukemia worldwide |
Race Oncology Ltd. |
Durbin plc |
Payment Unspecified |
4/11/18 |
Samsung Bioepis to settle patent litigation with Abbvie for SB-5 worldwide |
Samsung Bioepis Co. Ltd. |
Abbvie Inc. |
Payment Unspecified |
4/5/18 |
Servier to develop Scandicure's inhibitors of a biological target for metabolic disease |
Scandicure AB |
Servier |
Payment Unspecified |
4/3/18 |
Shanghai Haihe Pharmaceutical and 3D Medicines to develop HH-185 against cancer and pulmonary fibrosis in mainland China, Taiwan, Hong Kong and Macau |
Shanghai Haihe Pharmaceutical Co. Ltd. |
3D Medicines |
Payment Unspecified |
4/27/18 |
Pharmbio Korea to develop and commercialize Shionogi's ospemifene for ospemifene for vulvar and vaginal atrophy in South Korea |
Shionogi & Co. Ltd. |
Pharmbio Korea Co. Ltd. |
Payment Unspecified |
4/17/18 |
Eli Lilly to develop encapsulated cell therapies using Sigilon's Afibromer technology for type 1 diabetes worldwide |
Sigilon Therapeutics Inc. |
Eli Lilly and Co. |
$473.00 |
4/4/18 |
Simcere to develop and commercialize Hitgen's discovered small molecule drugs using DNA-encoded library design, synthesis and screening platform |
Simcere Pharmaceutical Group |
Hitgen Ltd. |
Payment Unspecified |
4/23/18 |
Jazz Pharmaceuticals to purchase Spark's rare pediatric disease priority review voucher of Luxturna for biallelic Rpe65 mutation-associated retinal dystrophy |
Spark Therapeutics LLC |
Jazz Pharmaceuticals plc |
$110.00 |
4/30/18 |
Taiho Pharmaceutical and Helsinn to develop TAS-0286 (HM-05) for non-small-cell lung cancer and other carcinomas |
Taiho Pharmaceutical Co. Ltd. |
Helsinn Group |
Payment Unspecified |
4/16/18 |
Fimecs to use Takeda Pharmaceutical's E3 ligase and pseudokinase targeting binders for development of of protein degradation therapeutics against cancer |
Takeda Pharmaceutical Co. Ltd. |
Fimecs Inc. |
Payment Unspecified |
4/10/18 |
Medison to distribute Tesaro's Zejula for all indications, excluding prostate cancer, in Israel |
Tesaro Inc. |
Medison Pharma Ltd. |
Payment Unspecified |
4/11/18 |
Kamada entered into a letter of intent to distribute Tetra Bio-pharma's PPP-001 in Israel for advanced cancer pain |
Tetra Bio-pharma Inc. |
Kamada Ltd. |
Payment Unspecified |
4/24/18 |
Dermavant to develop and commercialize Theravida's RVT-504 for hyperhidrosis |
Theravida Inc. |
Dermavant Sciences Inc. |
Payment Unspecified |
4/3/18 |
Apollobio to develop and commercialize Tocagen's Toca-511 and Toca-FC for high grade glioma in greater China |
Tocagen Inc. |
Apollobio Corp. |
$127.00 |
4/18/18 |
Topas Therapeutics and Boehringer to develop virus-based therapeutics |
Topas Therapeutics GmbH |
Boehringer Ingelheim International GmbH |
Payment Unspecified |
4/24/18 |
Pharmbio to develop and commercialize Trevena's oliceridine for pain in South Korea |
Trevena Inc. |
Pharmbio Korea Co. Ltd. |
$3.00 |
4/27/18 |
Biotechpharma UAB to manufacture Thevax Genetics Vaccine's hepatitis B virus vaccine for clinical trials |
UAB Biotechnologines Farmacijos Centras "Biotechpharma" |
Thevax Genetics Vaccine Co. Ltd. |
Payment Unspecified |
4/30/18 |
Forma to design and develop deubiquitylase enzyme inhibitors using Ubiquigent's Dubprofiler platform |
Ubiquigent Ltd. |
Forma Therapeutics Inc. |
Payment Unspecified |
4/5/18 |
Loxo Oncology to use Veracyte's Afirma Xpression Atlas platform to advance medicines for patients with cancers, including thyroid cancer |
Veracyte Inc. |
Loxo Oncology Inc. |
Payment Unspecified |
4/11/18 |
Wave Life and Deep Genomics to identify therapies for genetic neuromuscular disorders |
Wave Life Sciences Ltd. |
Deep Genomics Inc. |
Payment Unspecified |
4/10/18 |
Wuxi's STA Pharmaceutical to manufacture Phoenix Molecular's PMD-026 for IND-enabling toxicology studies and a phase I study in triple-negative breast cancer |
Wuxi Pharmatech (Cayman) Inc. |
Phoenix Molecular Designs |
Payment Unspecified |
4/16/18 |
May | ||||
Accenture to provide clinical data management services for the development of Genprex's Oncoprex against non-small-cell lung cancer |
Accenture |
Genprex Inc. |
Payment Unspecified |
5/8/18 |
AGC Biologics to manufacture and supply Horizon's teprotumumab for thyroid eye disease |
AGC Biologics |
Horizon Pharma plc |
Payment Unspecified |
5/3/18 |
Akums Drugs and Pharmaceuticals to manufacture and supply products containing Optibiotix's LP-LDL strain in India |
Akums Drugs & Pharmaceuticals Ltd. |
Optibiotix Health plc |
Payment Unspecified |
5/16/18 |
Astellas to develop and commercialize Aquinox's rosiptor for interstitial cystitis/bladder pain syndrome in the Asia-Pacific region, including Japan and excluding China and India |
Aquinox Pharmaceuticals Inc. |
Astellas Pharma Inc. |
$155.00 |
5/9/18 |
Outpost Medicine to develop Arena Pharmaceuticals' undisclosed G protein-coupled receptor-targeted preclinical compound for genitourinary disorders worldwide |
Arena Pharmaceuticals Inc. |
Outpost Medicine |
$103.00 |
5/1/18 |
KC Pharmaceuticals to develop and commercialize Ascendia's five over-the-counter sterile ophthalmic drop medicines |
Ascendia Pharmaceuticals LLC |
KC Pharmaceuticals |
Payment Unspecified |
5/8/18 |
Luye Pharma to purchase Astrazeneca's Seroquel and Seroquel XR in the U.K., China and other international markets |
Astrazeneca plc |
Luye Pharma Group Ltd. |
$538 |
5/8/18 |
Bactevo and Boehringer Ingelheim to discover small molecule lead compounds |
Bactevo Ltd. |
Boehringer Ingelheim International GmbH |
Payment Unspecified |
5/2/18 |
Biomatrix Specialty Pharmacy to distribute Shire's Vonvendi against von Willebrand disease |
Biomatrix Specialty Pharmacy LLC |
Shire plc |
Payment Unspecified |
5/3/18 |
Catalent to manufacture Valerius' biosimilar products using Gpex technology |
Catalent Inc. |
Valerius Biopharma AG |
Payment Unspecified |
5/14/18 |
CSL to develop, manufacture and commercialize Cevec Pharmaceutical's recombinant C1 esterase inhibitor against hereditary angioedema using Capgo technology |
Cevec Pharmaceuticals GmbH |
CSL Ltd. |
Payment Unspecified |
5/8/18 |
Chongqing Zhifei Biological Products to distribute Merck's nonavalent human papillomavirus vaccine in China |
Chongqing Zhifei Biological Products Co. Ltd. |
Merck & Co. Inc. |
Payment Unspecified |
5/2/18 |
Carna to develop AS-871 for autoimmune diseases using Evotec's Indigo platform |
Evotec AG |
Carna Biosciences Inc. |
Payment Unspecified |
5/8/18 |
Carna to use Evotec's Indigo platform to accelerate and develop CB-1763 against blood cancer |
Evotec AG |
Carna Biosciences Inc. |
Payment Unspecified |
5/8/18 |
Ferring to commercialize FKD's nadofaragene firadenovec for nonmuscle-invasive bladder cancer worldwide |
FKD Therapies Oy |
Ferring Pharmaceuticals SA |
Payment Unspecified |
5/3/18 |
Goodwin to provide cGMP manufacturing for Telix Pharmaceutical's TLX-250 in a phase III clinical study against renal cell cancer |
Goodwin Biotechnology Inc. |
Telix Pharmaceuticals Ltd. |
Payment Unspecified |
5/2/18 |
Hemogenyx and an undisclosed pharmaceutical company to develop bispecific CDX antibodies for bone marrow transplants |
Hemogenyx Pharmaceuticals Ltd. |
Undisclosed |
Payment Unspecified |
5/14/18 |
Indivior to settle patent infringement litigation with Par Pharmaceutical for a generic version of suboxone sublingual film |
Indivior plc |
Par Pharmaceutical Inc. |
Payment Unspecified |
5/14/18 |
Lunatus to commercialize Insys' Subsys for pain in the Middle East |
Insys Therapeutics Inc. |
Lunatus |
Payment Unspecified |
5/8/18 |
Exelixis and Invenra to discover and develop multispecific antibodies against cancer using B-body technology platform worldwide |
Invenra Inc. |
Exelixis Inc. |
$470.50 |
5/2/18 |
Iontas and Aten to discover therapeutic oncology leads |
Iontas Ltd. |
Aten Therapeutics Ltd. |
Payment Unspecified |
5/2/18 |
Ixcells to use iPS Academia's patents related to induced pluripotent stem cells for research |
iPS Academia Japan Inc. |
Ixcells Biotechnologies |
Payment Unspecified |
5/16/18 |
Scythian to import and distribute Isodiol's cannabidiol products to certain countries in the Caribbean, Central America and South America |
Isodiol International Inc. |
Scythian Biosciences Corp. |
$2.00 |
5/7/18 |
Vivus to acquire assets related to Janssen Pharmaceuticals' Pancreaze in the U.S. and Canada |
Janssen Pharmaceuticals Inc. |
Vivus Inc. |
$135.00 |
5/1/18 |
La Jolla to sell Giapreza's royalty rights to Healthcare Royalty Partners |
La Jolla Pharmaceutical Co. |
Healthcare Royalty Partners |
$125.00 |
5/10/18 |
Utility Therapeutics to develop LEO Pharma's antibiotics, mecillinam and and pivmecillinam, for complicated urinary tract infections in the U.S. |
LEO Pharma A/S |
Utility Therapeutics Ltd. |
Payment Unspecified |
5/15/18 |
Jiangsu to develop and commercialize Lidds' Liproca Depot for prostate cancer in China |
Lidds AB |
Jiangsu Ambition Medical |
$1.00 |
5/16/18 |
Linde to distribute Neuroprotexeon's Xenex for post cardiac arrest syndrome in European Union including the U.K., Switzerland, Norway and Iceland |
Linde AG |
Neuroprotexeon |
$28.26 |
5/9/18 |
Anji Pharma to sublicense Lipimetix's AEM-28-08, AEM-28 and AEM-28-14 in mainland China, Taiwan and Hong Kong |
Lipimetix Development LLC |
Anji Pharmaceuticals Inc. |
$3.10 |
5/7/18 |
Genentech to use Lodo's genome mining and biosynthetic cluster assembly platform to identify molecules for multiple disease-related targets |
Lodo Therapeutics Corp. |
Genentech Inc. |
$969.00 |
5/9/18 |
Provention to develop and commercialize Macrogenics' MGD-010 for systemic lupus erythematosus worldwide |
Macrogenics Inc. |
Provention Bio Inc. |
$290.00 |
5/7/18 |
Provention to purchase Macrogenics' teplizumab for type 1 diabetes |
Macrogenics Inc. |
Provention Bio Inc. |
$395.00 |
5/7/18 |
Cipla to distribute Mannkind's Afrezza for diabetes mellitus in India |
Mannkind Corp. |
Cipla Ltd. |
$2.20 |
5/9/18 |
Mckesson to distribute Aclaris' Eskata 40% (w/w) topical solution for raised seborrheic keratoses in the U.S. |
Mckesson Corp. |
Aclaris Therapeutics Inc. |
Payment Unspecified |
5/7/18 |
Ritter Pharmaceuticals to conduct phase III study for Medpace's RP-G28 for lactose intolerance |
Medpace Inc. |
Ritter Pharmaceuticals Inc. |
Payment Unspecified |
5/3/18 |
SFJ Pharmaceuticals to collaborate on development of Merck's abituzumab combination with Erbitux for metastatic colorectal cancer |
Merck KGaA |
SFJ Pharmaceuticals Inc. |
Payment Unspecified |
5/2/18 |
Mithra to provide development and manufacturing services to Midas Pharma for a sterile injectable product |
Mithra Pharmaceuticals |
Midas Pharma GmbH |
Payment Unspecified |
5/16/18 |
Kyorin to distribute MSD's nasonex nasal for allergic rhinitis for Japan |
MSD Japan |
Kyorin Holdings Inc. |
Payment Unspecified |
5/10/18 |
Sarepta Therapeutics to develop and commercialize Myonexus Therapeutics' five Limb-girdle muscular dystrophy gene therapy candidates, with an option to acquire Myonexus |
Myonexus Therapeutics Inc. |
Sarepta Therapeutics Inc. |
$105.00 |
5/3/18 |
Neoimmunetech to evaluate Hyleukin-7 in combination with Roche's atezolizumab in three skin cancer types |
Neoimmunetech Inc. |
Roche Holding AG |
Payment Unspecified |
5/1/18 |
Axim to purchase Noramco's active pharmaceutical ingredient to advance the clinical trials of dronabinol for chemotherapy-induced nausea and vomiting and anorexia |
Noramco Inc. |
Axim Biotechnologies Inc. |
Payment Unspecified |
5/7/18 |
Vitrisa to acquire Ohr's clinical data from the Mako study of squalamine lactate in wet age-related macular degeneration worldwide |
Ohr Pharmaceutical Inc. |
Vitrisa Therapeutics Inc. |
Payment Unspecified |
5/16/18 |
Pantherx Specialty Pharmacy to distribute Otsuka America Pharmaceutical's tolvaptan against autosomal dominant polycystic kidney disease |
Pantherx Specialty Pharmacy |
Otsuka America Pharmaceutical Inc. |
Payment Unspecified |
5/10/18 |
Pharmaceutical Research Management to conduct first-in-man clinical trials for Esperite's CF-MEV-107 against Crohn's disease |
Pharmaceutical Research Management srl |
Esperite NV |
Payment Unspecified |
5/17/18 |
Astrazeneca and Procella to develop cardiovascular and catheter-based therapies |
Procella Therapeutics AB |
Astrazeneca plc |
$320.00 |
5/7/18 |
Profectus and Medisun to form Promed Biosciences for the development of vaccines against infectious diseases and cancer using Pbsvax technology in Asia |
Profectus Biosciences Inc. |
Medisun International Ltd. |
Payment Unspecified |
5/17/18 |
Rxi Pharmaceuticals to study its self-delivering RNAi technology to advance immuno-oncology therapeutics with Iovance's tumor-infiltrating lymphocytes for solid tumors |
Rxi Pharmaceuticals Corp. |
Iovance Biotherapeutics Inc. |
Payment Unspecified |
5/11/18 |
Abcam to enter into a memorandum of understanding with Shuwen to develop and commercialize companion diagnostic kits |
Shuwen Biotech Co. Ltd. |
Abcam plc |
Unknown |
5/7/18 |
Solara to provide contract manufacturing and supply services to Strides Shasun for the active pharmaceutical ingredient of cinacalcet hydrochloride |
Solara Active Pharma Sciences Ltd. |
Strides Shasun Ltd. |
Payment Unspecified |
5/2/18 |
Azevedos Industria to sign a letter of intent to distribute Tetra Bio-pharma's PPP-001 in Portugal for advanced cancer pain |
Tetra Bio-pharma Inc. |
Azevedos Industria Farmaceutica SA |
Payment Unspecified |
5/4/18 |
Spectrum to use TFS' Oncomine Dx Target Test as a companion diagnostic for poziotinib against non-small-cell lung cancer |
Thermo Fisher Scientific Inc. |
Spectrum Pharmaceuticals Inc. |
Payment Unspecified |
5/1/18 |
Notes This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Cortellis. |